三鑫医疗
(300453)
| 流通市值：34.51亿 | | | 总市值：49.27亿 |
| 流通股本：3.66亿 | | | 总股本：5.22亿 |
| 报告期 | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 1,305,189,368.04 | 836,722,599.37 | 408,868,947.98 | 1,640,195,872.45 |
| 营业收入 | 1,305,189,368.04 | 836,722,599.37 | 408,868,947.98 | 1,640,195,872.45 |
| 二、营业总成本 | 1,064,589,216.16 | 680,824,909.16 | 327,089,393.18 | 1,341,418,619.08 |
| 营业成本 | 837,256,546.33 | 532,588,480.23 | 257,144,688.58 | 1,049,334,446.5 |
| 税金及附加 | 12,407,181.15 | 8,052,559.49 | 4,002,324.29 | 15,902,609.28 |
| 销售费用 | 59,620,249.25 | 38,871,854.78 | 18,820,321.21 | 77,851,326.4 |
| 管理费用 | 88,204,488.79 | 57,752,155.41 | 27,578,366.44 | 122,584,342.65 |
| 研发费用 | 60,935,757.15 | 39,516,289.94 | 17,803,714.48 | 75,279,472.51 |
| 财务费用 | 6,164,993.49 | 4,043,569.31 | 1,739,978.18 | 466,421.74 |
| 其中:利息费用 | 3,442,462.55 | 1,673,011.92 | 712,349.92 | 1,820,898.77 |
| 其中:利息收入 | 1,173,842 | 498,207.47 | 321,784.41 | 1,161,976.28 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 2,783,597.39 | 1,995,338.46 | 1,418,280.62 | 105,104.94 |
| 加:投资收益 | 1,816,798.19 | 1,519,659.97 | 451,112.86 | 10,531,761.76 |
| 资产处置收益 | -435.84 | -22,433.85 | - | -854,608.2 |
| 资产减值损失(新) | -500,423.81 | -584,956.42 | -284,185.62 | -6,852,149.34 |
| 信用减值损失(新) | -1,343,005.44 | -3,046,526.12 | -2,044,825.92 | -3,835,306.65 |
| 其他收益 | 17,445,592.02 | 11,648,856.52 | 5,926,813.11 | 27,508,260.27 |
| 四、营业利润 | 260,802,274.39 | 167,407,628.77 | 87,246,749.85 | 325,380,316.15 |
| 加:营业外收入 | 1,153,373.44 | 200,918.27 | 111,795.2 | 2,519,016.11 |
| 减:营业外支出 | 4,942,176.79 | 4,518,628.61 | 9,335.57 | 3,656,789.85 |
| 五、利润总额 | 257,013,471.04 | 163,089,918.43 | 87,349,209.48 | 324,242,542.41 |
| 减:所得税费用 | 27,451,381.27 | 18,040,852.4 | 11,926,861.54 | 33,973,819.77 |
| 六、净利润 | 229,562,089.77 | 145,049,066.03 | 75,422,347.94 | 290,268,722.64 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 229,562,089.77 | 145,049,066.03 | 75,422,347.94 | 290,268,722.64 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 210,284,122.16 | 132,115,861.37 | 68,356,641.86 | 264,937,745.44 |
| 少数股东损益 | 19,277,967.61 | 12,933,204.66 | 7,065,706.08 | 25,330,977.2 |
| 扣除非经常损益后的净利润 | 193,003,645.58 | 121,609,218.46 | 61,240,212.53 | 241,656,364.78 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.4 | 0.25 | 0.13 | 0.51 |
| (二)稀释每股收益 | 0.4 | 0.25 | 0.13 | 0.51 |
| 九、综合收益总额 | 229,562,089.77 | 145,049,066.03 | 75,422,347.94 | 290,268,722.64 |
| 归属于母公司股东的综合收益总额 | 210,284,122.16 | 132,115,861.37 | 68,356,641.86 | 264,937,745.44 |
| 归属于少数股东的综合收益总额 | 19,277,967.61 | 12,933,204.66 | 7,065,706.08 | 25,330,977.2 |
| 公告日期 | 2026-10-16 | 2026-08-25 | 2026-04-27 | 2026-04-27 |
| 审计意见(境内) | | | | 标准无保留意见 |